@article{3142235,
    title = "Amisulpride for the treatment of very-late-onset schizophrenia-like
psychosis",
    author = "Psarros, Constantin and Theleritis, Christos G. and Paparrigopoulos, and Thomas J. and Politis, Antonios M. and Papadimitriou, George N.",
    journal = "International Journal of Geriatric Psychiatry",
    year = "2009",
    volume = "24",
    number = "5",
    pages = "518-522",
    publisher = "Wiley",
    issn = "0885-6230, 1099-1166",
    doi = "10.1002/gps.2146",
    keywords = "amisulpride; psychosis in the elderly; treatment; very-late-onset
schizophrenia-like psychosis",
    abstract = "Background Although schizophrenia affects all age groups, late or
very-late-onset schizophrenia-like psychosis has not been well studied
and various treatment issues remain unresolved. The objective of the
present study was to evaluate the efficacy and safety of amisulpride
monotherapy in a diagnostically homogeneous group of elderly patients
without cognitive impairment suffering from very-late-onset
schizophrenia.
Methods Twenty-six patients of mean age 76.2 +/- 5.8 years, fulfilling
both the recent consensus criteria for very late-onset
schizophrenia-like psychosis and the DSM-IV-TR criteria for
schizophrenia, were assessed by the Brief Psychiatric Rating Scale, the
Clinical Global Impression Scale and the Positive and Negative Syndrome
Scale at baseline and five weeks following amisulpride (50-200 mg/day)
administration; also, the presence of abnormal movements was evaluated
with the Simpson-Angus Scale, the Barnes Akathisia Scale, and the
Abnormal Involuntary Movement Scale.
Results A highly significant (p < 0.001) improvement on all measures of
psychotic symptomatology was observed in all patients. Amisulpride was
very well tolerated by the patients and no clinically significant
adverse effects were observed. Scores on all abnormal movement scales
did not differ significantly prior to and after amisulpride treatment.
Conclusion Preliminary results indicate that amisulpride appears to be
an efficacious and safe atypical antipsychotic for the treatment of
very-late-onset schizophrenia-like psychosis. Copyright (C) 2008 John
Wiley & Sons, Ltd."
}